US-based medical device company STAAR Surgical has obtained approval from the Medical Devices Bureau of Health Canada to distribute EVO Visian Toric ICL in the country.

Staar's EVO Visian Toric ICL has been developed as a next-generation lens implanted in the eye that works with the patient's natural eye to repair their vision.

The EVO Toric ICL is placed inside the eye between the iris and the natural lens where it can stay for an indefinite amount of time.

"This represents an important new option for eligible patients between 21 and 45 years old living with nearsightedness and astigmatism treated in a single procedure."

The lens is made of Staar Surgical's patented collamer which is a collagen based material, an organic compound which characterises the lens' ability to work with the natural lens of the eye.

The EVO ICL, with its central hole, allows enhanced refractive outcomes while ensuring efficiency and comfort for both the patient and the surgeon by eliminating the extra surgical step of the peripheral iridotomy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Staar president and CEO Caren Mason said: "We are very pleased with Health Canada's approval that allows us to offer the EVO Toric ICL for myopia and astigmatism, with a broad spherical power range of -3.0 to -18.0 diopters and cylinder power range of 1.0 to 6.0 diopters, to our surgeons and their patients in Canada.

"This represents an important new option for eligible patients between 21 and 45 years old living with nearsightedness and astigmatism treated in a single procedure."

Till date, the company records implanting more than 200,000 lenses from the EVO ICL product family.